Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Expired warrants

<< Previous

Bullboard Posts

Next >>

Comment by Doccoleon Feb 28, 2022 12:42pm

135 Views

Post# 34468153

RE:RE:Expired warrants

Do you anticipate a run?

I remember a question to Dan several months ago about market cap and what companies trade at during certain phases.

for a phase 2 company- is there a multiple that companies generally trade at? 100m -300m? I imagines the biz study being released will help.

we are due for positive catalysts!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing